TVTX compared with IVVD: revenue, margins and what each company keeps, and the suppliers and customers both name

TVTXTravere Therapeutics, Inc.

Mkt capRevenueRevenue

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

Compare

TVTXTravere Therapeutics, Inc.

IVVDInvivyd, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

TVTX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±13.4%▲+12.03%×0.90

Q1 FY26±6.8%▼−0.24%×0.03

Feb 20 '26±9.4%▲+3.72%×0.39

Jan 13 '26±31.8%▼−14.63%×0.46

IVVD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±48.9%▲+5.13%×0.10

= impliedTVTX realized, solidIVVD realized, hatchedOne scale, both sides: full bar = 49%× = |realized| ÷ impliedSource: market data

TVTXTravere Therapeutics, Inc.

49.12▼−2.53%

Mkt cap$4.7BRevenue$170MQ2 FY26Revenue$491MFY25

IVVDInvivyd, Inc.

0.57▼−1.31%

Regular sessionNov 2 '26

Mkt cap$171.5MRevenue$14MQ2 FY26Revenue$53MFY25

Compare

Regular sessionNov 2 '26

TVTXTravere Therapeutics, Inc.

IVVDInvivyd, Inc.

49.12▼−2.53%

Price

0.57▼−1.31%

$4.7B

Mkt cap

$171.5M

Q2 FY26$170M

Revenue

$14MQ2 FY26

FY25$491M

Revenue

$53MFY25

TVTX49.12▼−2.53%vsIVVD0.57▼−1.31%Regular sessionNov 2 '26